CN115835879A - Stat3磷酸化抑制剂、自身免疫性疾病和冠状病毒传染病的预防或治疗剂 - Google Patents

Stat3磷酸化抑制剂、自身免疫性疾病和冠状病毒传染病的预防或治疗剂 Download PDF

Info

Publication number
CN115835879A
CN115835879A CN202180035683.2A CN202180035683A CN115835879A CN 115835879 A CN115835879 A CN 115835879A CN 202180035683 A CN202180035683 A CN 202180035683A CN 115835879 A CN115835879 A CN 115835879A
Authority
CN
China
Prior art keywords
stc1
coronavirus
therapeutic agent
active ingredient
stanniocalcin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035683.2A
Other languages
English (en)
Chinese (zh)
Inventor
大河内真也
兼平雅彦
冈田克典
黑泽一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Publication of CN115835879A publication Critical patent/CN115835879A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180035683.2A 2020-06-30 2021-03-01 Stat3磷酸化抑制剂、自身免疫性疾病和冠状病毒传染病的预防或治疗剂 Pending CN115835879A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-112680 2020-06-30
JP2020112680 2020-06-30
PCT/JP2021/007780 WO2022004054A1 (ja) 2020-06-30 2021-03-01 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤

Publications (1)

Publication Number Publication Date
CN115835879A true CN115835879A (zh) 2023-03-21

Family

ID=79315687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035683.2A Pending CN115835879A (zh) 2020-06-30 2021-03-01 Stat3磷酸化抑制剂、自身免疫性疾病和冠状病毒传染病的预防或治疗剂

Country Status (5)

Country Link
US (1) US20230201310A1 (https=)
EP (1) EP4194004A4 (https=)
JP (2) JP7702150B2 (https=)
CN (1) CN115835879A (https=)
WO (1) WO2022004054A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732831B (zh) * 2022-04-25 2023-06-23 齐鲁理工学院 斯钙素-1作为调节肿瘤微环境的标志物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008681A1 (ja) * 2011-07-09 2013-01-17 国立大学法人東北大学 線維症予防又は治療用医薬組成物
CN105263510A (zh) * 2013-05-10 2016-01-20 奥尔胡斯大学 冠毛素调节剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2387685A1 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon
US8759298B2 (en) * 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008681A1 (ja) * 2011-07-09 2013-01-17 国立大学法人東北大学 線維症予防又は治療用医薬組成物
CN105263510A (zh) * 2013-05-10 2016-01-20 奥尔胡斯大学 冠毛素调节剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG, L.等: "Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury", SCIENTIFIC REPORTS, vol. 5, no. 18117, 7 December 2015 (2015-12-07), pages 1 - 13 *
WU, Y.等: "Upregulation of stanniocalcin-1 inhibits the development of osteoarthritis by inhibiting survival and inflammation of fibroblast-like synovial cells", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 120, no. 12, 23 December 2018 (2018-12-23), pages 9768 - 9780 *

Also Published As

Publication number Publication date
JP7702150B2 (ja) 2025-07-03
US20230201310A1 (en) 2023-06-29
JP2025109968A (ja) 2025-07-25
EP4194004A1 (en) 2023-06-14
WO2022004054A1 (ja) 2022-01-06
TW202207972A (zh) 2022-03-01
JPWO2022004054A1 (https=) 2022-01-06
EP4194004A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
CN110200981A (zh) 五环三萜皂苷的医药用途及其药物组合物
KR102174576B1 (ko) 바이러스 질환 치료에서의 ｍｅｋ 억제제
CN114786659A (zh) 用于治疗汉坦病毒感染的mek抑制剂
EP3900717A1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
US20230159594A1 (en) Compounds for use in viral infections
CN108815158A (zh) 全霉素在抑制nlrp3炎症小体活化中的应用
WO2023232095A1 (zh) 一种基于病毒阻断剂的口腔喷雾制剂及其用途
Hur et al. MicroRNA-21 inhibition attenuates airway inflammation and remodelling by modulating the transforming growth factor β–Smad7 pathway
JP2025109968A (ja) Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤
CN101559049B (zh) 肝纤维化抑制剂
He et al. C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus
KR102843222B1 (ko) 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
JP2023530431A (ja) コロナウイルスを治療するための化合物および方法
US20230270826A1 (en) Antiviral use of liraglutide and gefitinib
TWI916376B (zh) Stat3之磷酸化抑制劑、自體免疫疾病及冠狀病毒傳染病之預防或治療劑
CN116492325A (zh) 以衣康酸为起点抑制Tet靶点蛋白的药物开发
CN103096885B (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
Teixeira Alves et al. Protective role of the HSP90 inhibitor, STA-9090, in lungs of SARS-CoV-2-infected Syrian golden hamsters
US20230406938A1 (en) USE OF FcgammaRIII INHIBITOR IN PREPARATION OF MEDICAMENT FOR TREATING PULMONARY FIBROSIS
WO2021181279A1 (en) Compositions and methods for treating covid-19 infections and/or symptoms thereof
KR20220033450A (ko) 니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
US20240216365A1 (en) Methods and uses of protein disulfide isomerase inhibitory compounds
CN119139378A (zh) 神香草挥发油及包含其的组合物在制备治疗特发性肺纤维化药物中的应用
CN121313835A (zh) Nufip2抑制剂在制备治疗流感病毒感染产品中的应用
KR102117525B1 (ko) Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination